Avalo Therapeutics (AVTX) Profit After Tax (2016 - 2025)
Historic Profit After Tax for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$30.6 million.
- Avalo Therapeutics' Profit After Tax fell 23293.83% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year decrease of 115506.41%. This contributed to the annual value of -$35.1 million for FY2024, which is 1136.51% down from last year.
- Avalo Therapeutics' Profit After Tax amounted to -$30.6 million in Q3 2025, which was down 23293.83% from -$20.8 million recorded in Q2 2025.
- In the past 5 years, Avalo Therapeutics' Profit After Tax registered a high of $98.5 million during Q2 2024, and its lowest value of -$121.3 million during Q1 2024.
- Over the past 5 years, Avalo Therapeutics' median Profit After Tax value was -$13.1 million (recorded in 2025), while the average stood at -$13.5 million.
- Within the past 5 years, the most significant YoY rise in Avalo Therapeutics' Profit After Tax was 130179.42% (2024), while the steepest drop was 111838.27% (2024).
- Over the past 5 years, Avalo Therapeutics' Profit After Tax (Quarter) stood at -$19.2 million in 2021, then skyrocketed by 48.78% to -$9.8 million in 2022, then increased by 16.75% to -$8.2 million in 2023, then tumbled by 332.65% to -$35.3 million in 2024, then grew by 13.34% to -$30.6 million in 2025.
- Its Profit After Tax stands at -$30.6 million for Q3 2025, versus -$20.8 million for Q2 2025 and -$13.1 million for Q1 2025.